Serum Inflammation Markers Predicting Successful Initial Catheter Ablation for Atrial Fibrillation

Heart Lung and Circulation

Volumn 23, Issue 7, 2014, Pages 636-643

  Kimura, Takehiro ^a   Takatsuki, Seiji ^a   Inagawa, Kohei ^a   Katsumata, Yoshinori ^a   Nishiyama, Takahiko ^a   Nishiyama, Nobuhiro ^a   Fukumoto, Kotaro ^a   Aizawa, Yoshiyasu ^a   Tanimoto, Yoko ^a   Tanimoto, Kojiro ^a   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Atrial fibrillation; Catheter ablation; Follow up, inflammation; Matrix metalloproteinase 2; Tumour necrosis factor

Indexed keywords

ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GELATINASE A; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN; PROCOLLAGEN; PROTEIN P1NP; PROTHROMBIN; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; MMP2 PROTEIN, HUMAN;

ADULT; ARTICLE; CATHETER; CATHETER ABLATION; CATHETER SHEATH; CLINICAL ARTICLE; ELECTROCARDIOGRAM; ELECTRODE CATHETER; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MALE; MAPPING CATHETER; PATIENT MONITORING; PRIORITY JOURNAL; PROGNOSIS; PULMONARY VEIN ISOLATION; RECURRENT DISEASE; RISK ASSESSMENT; SINUS RHYTHM; AGED; ATRIAL FIBRILLATION; BLOOD; CLINICAL TRIAL; INFLAMMATION; MIDDLE AGED;

AGED; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CATHETER ABLATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 2; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902002506     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2014.02.003     Document Type: Article

References (23)

1. Platonov P.G., Mitrofanova L.B., Orshanskaya V., Ho S.Y. Structural abnormalities in atrial walls are associated with presence and persistency of atrial fibrillation but not with age. J Am Coll Cardiol 2011, 58:2225-2232.
2. Chung M.K., Martin D.O., Sprecher D., Wazni O., Kanderian A., Carnes C.A., et al. C-reactive protein elevation in patients with atrial arrhythmias: inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001, 104:2886-2891.
3. Tziakas D.N., Chalikias G.K., Papanas N., Stakos D.A., Chatzikyriakou S.V., Maltezos E. Circulating levels of collagen type I degradation marker depend on the type of atrial fibrillation. Europace 2007, 9:589-596.
4. Henningsen K.M., Nilsson B., Bruunsgaard H., Chen X., Pedersen B.K., Svendsen J.H. Prognostic impact of hs-CRP and IL-6 in patients undergoing radiofrequency catheter ablation for atrial fibrillation. Scand Cardiovasc J 2009, 43:285-291.
5. Yamashita T., Inoue H., Okumura K., Kodama I., Aizawa Y., Atarashi H., et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace 2011, 13:473-479.
6. Negi S., Shukrullah I., Veledar E., Bloom H.L., Jones D.P., Dudley S.C. Statin therapy for the prevention of atrial fibrillation trial (SToP AF trial). J Cardiovasc Electrophysiol. 2011, 22:414-419.
7. Calkins H., Brugada J., Packer D.L., Cappato R., Chen S.A., Crijns H.J., et al. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm 2007, 4:816-861.
8. Haissaguerre M., Jais P., Shah D.C., Takahashi A., Hocini M., Quiniou G., et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998, 339:659-666.
9. Tops L.F., Bax J.J., Zeppenfeld K., Jongbloed M.R., Lamb H.J., van der Wall E.E., et al. Fusion of multislice computed tomography imaging with three-dimensional electroanatomic mapping to guide radiofrequency catheter ablation procedures. Heart Rhythm. 2005, 2:1076-1081.
10. Abreu Filho C.A., Lisboa L.A., Dallan L.A., Spina G.S., Grinberg M., Scanavacca M., et al. Effectiveness of the maze procedure using cooled-tip radiofrequency ablation in patients with permanent atrial fibrillation and rheumatic mitral valve disease. Circulation. 2005, 112:I20-I25.
11. Chao T.F., Lin Y.J., Tsao H.M., Tsai C.F., Lin W.S., Chang S.L., et al. CHADS(2) and CHA(2)DS(2)-VASc scores in the prediction of clinical outcomes in patients with atrial fibrillation after catheter ablation. J Am Coll Cardiol. 2011, 58:2380-2385.
12. Berruezo A., Tamborero D., Mont L., Benito B., Tolosana J.M., Sitges M., et al. Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. Eur Heart J. 2007, 28:836-841.
13. Shim J., Joung B., Park J.H., Uhm J.S., Lee M.H., Pak H.N. Long duration of radiofrequency energy delivery is an independent predictor of clinical recurrence after catheter ablation of atrial fibrillation: Over 500 cases experience. Int J Cardiol. 2012.
14. Hussein A.A., Saliba W.I., Martin D.O., Shadman M., Kanj M., Bhargava M., et al. Plasma B-type natriuretic peptide levels and recurrent arrhythmia after successful ablation of lone atrial fibrillation. Circulation. 2011, 123:2077-2082.
15. Adlbrecht C., Gwechenberger M., Richter B., Sipotz J., Kaider A., Gossinger H. Prognostic value of induction of atrial fibrillation before and after pulmonary vein isolation. Int J Cardiol. 2011.
16. Rostock T., Salukhe T.V., Steven D., Drewitz I., Hoffmann B.A., Bock K., et al. Long-term single- and multiple-procedure outcome and predictors of success after catheter ablation for persistent atrial fibrillation. Heart Rhythm 2011, 8:1391-1397.
17. Kalogeropoulos A.S., Tsiodras S., Rigopoulos A.G., Sakadakis E.A., Triantafyllis A., Kremastinos D.T., et al. Novel association patterns of cardiac remodeling markers in patients with essential hypertension and atrial fibrillation. BMC Cardiovasc Disord. 2011, 11:77.
18. Wang W., Wu P.S., Yang X.L. [Role of matrix metalloproteinase and tissue inhibitor of metalloproteinase in atrial structural remodeling in patients with atrial fibrillation]. Nan Fang Yi Ke Da Xue Xue Bao. 2010, 30:1160-1162.
19. Kato K., Fujimaki T., Yoshida T., Oguri M., Yajima K., Hibino T., et al. Impact of matrix metalloproteinase-2 levels on long-term outcome following pharmacological or electrical cardioversion in patients with atrial fibrillation. Europace. 2009, 11:332-337.
20. Okumura Y., Watanabe I., Nakai T., Ohkubo K., Kofune T., Kofune M., et al. Impact of biomarkers of inflammation and extracellular matrix turnover on the outcome of atrial fibrillation ablation: importance of matrix metalloproteinase-2 as a predictor of atrial fibrillation recurrence. J Cardiovasc Electrophysiol. 2011, 22:987-993.
21. Marin F., Roldan V., Climent V., Garcia A., Marco P., Lip G.Y. Is thrombogenesis in atrial fibrillation related to matrix metalloproteinase-1 and its inhibitor, TIMP-1?. Stroke 2003, 34:1181-1186.
22. Deng H., Xue Y.M., Zhan X.Z., Liao H.T., Guo H.M., Wu S.L. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin Med J (Engl) 2011, 124:1976-1982.
23. Cagli K.E., Aras D., Topaloglu S., Geyik B., Ayaz S., Cagirci G., et al. Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty. Heart Vessels. 2010, 25:131-137.